Patent Document ID: 20150240312
Application ID: 14407913
Patent Flag: 0

Claim One:
1. A method of predicting the likelihood of long-term survival without recurrence of cancer for a subject having estrogen receptor-positive (ER+) breast cancer treated with endocrine monotherapy, the method comprising; a) obtaining a breast cancer tissue sample from a human subject; b) determining in the sample, expression levels of endocrine therapy sensitivity genes PARP3, AZGP1, EPHX2, IGFBP4, NUDT18, FMO5, C1orf66, COL14A1, PLAT, PCM1, ZBTB20, NFKB1, TK2, ABAT, ACP6, TSPAN7, TNFRSF10B, OSBPL1A, KCTD9, EVL, MAP2K4, RPL21, STC2, ZNF18, PHYHD1 and CHDH, and endocrine therapy resistance genes CENPE, CCNB1, KIFC1, CCT6A, EIF2C2, RAD54B, VDAC2, MCM10, ZWINT, KIF18A, RACGAP1, TDG, NUP107, TMPO, XPOT, BIRC5, TOP2A, DSC2, EIF2S2, UBE2C, TPX2, C20orf24, KIF4A, CDC2, CDCA5, C8orf76 and FBXO45, using a fluorescent barcoded hybridization assay; and c) assigning the subject to a sensitive, indeterminate or resistant group, wherein assignment to a sensitive group predicts longer relapse-free survival compared to the resistant group, wherein the assigning the subject to a sensitive, indeterminate or resistant group comprises determining the gene centroid of the endocrine therapy sensitivity genes and the gene centroid of the endocrine therapy resistance genes.